The researchers took a retrospective economic evaluation of cost-per-survivor without someone neurodevelopmental impairment by using data-patient from caffeine for Sleep Apnea Prematurity clinical trial (N = 1869).
Researchers include direct medical expenses or claims payer or hospital but excluding costs for parents and society, such as loss of productivity. Our price $ 0.00/mg of caffeine citrate generic for our base-case analysis. All expenditure shall be expressed in dollars Canada 2008 and discounted at 3%. The time horizon for the analysis is extended through 18 and 21 months corrected age to match the clinical trial.
The average cost per infant was $ 124 466 in caffeine and $ 133 505 in the placebo group (difference: $ 9039 [–14 749 to – 375] corrected P =. 014).
Cost-effectiveness analysis showed that caffeine is a dominant position or "win-win" therapies: > 99% of 1000 bootstrap propagation analysis, caffeine-treated infants had lower average costs and simultaneously better results. These results were strong in 1000% increase in elements of individual resource, including the price of caffeine citrate.
Compared with placebo therapies caffeine for Sleep Apnea of prematurity in infants weighing less than 1250 g financially attractive for infants up to 18 and 21 months corrected age.
Tagged with:caffeine ‧ clinical trial ‧ direct cost medical ‧ Sleep Apnea babies ‧ insurance payer ‧ Sleep Apnea Kids ' ‧ ‧ Sleep Apnea Sleep Apnea in children
Filed under:clinical research sleep ‧ ‧ ‧ Sleep Apnea ‧ ‧ Sleep Apnea research Sleep Apnea treatment ‧ ‧ Sleep Apnea in children who sleep problems clinical trials
Like this post? subscribe to my RSS feed and get loads more!
沒有留言:
張貼留言